Table 2 Demographic and clinical characteristics of the study population with AF at baseline according to major bleeding event

Age (y)

7 3.7 ± 10.0

71.9 ± 12.0

0.42

Gender male n (%)

94 (39)

10 (42)

0.83

DM n (%)

169 (70)

16 (67)

0.82

Dialysis vintage (years)

0.0 (0.0–3.0)

0.0 (0.0–3.8)

0.83

Kt/V

1.36 ± 0.17

1.26 ± 0.25

0.006

Vascular access

0.46

 Arterio-venous fistula n (%)

89 (37)

11 (46)

 Arterio-venous graft n (%)

17 (7)

4 (17)

 Central venous catheter n (%)

136 (56)

9 (37)

Heparin dose during HD session (units)

2500 (0–2500)

1250 (0–2500)

0.33

Comorbidity index

8.7 ± 3.2

9.0 ± 3.1

0.63

Functional status (need in nursing care) n (%)

142 (59)

9 (37)

0.03

Dementia n (%)

43 (18)

4 (17)

0.90

A-V access thrombosis n (%)

50 (21)

7 (29)

0.43

Left atrium size (cm)

4.3 ± 0.6

4.4 ± 0.5

0.54

Time since AF diagnosis (years)

4.0 (1.0–7.0)

2.0 (0.0–6.0)

0.26

All-cause death n (%)

193 (80)

21 (88)

0.59

Warfarin use n (%)

82 (34)

9 (37)

0.82

Aspirin use n (%)

137 (57)

16 (67)

0.39

Clopidogrel use n (%)

54 (22)

7 (29)

0.45

Dual antiplatelet therapy n (%)

34 (14)

7 (29)

0.07

Enoxaparin use n (%)

31 (13)

3 (12)

0.69

PPI n (%)

130 (54)

17 (71)

0.13

INR

1.2 (1.1–1.4)

1.3 (1.1–1.7)

0.41

Hb (g/dL)

10.1 ± 1.7

9.5 ± 1.7

0.40

Platelets(×10³/mm³)

196.8 ± 73.4

184.9 ± 63.6

0.47

Mean HAS-BLED score

4.5 ± 1.2

4.4 ± 1.1

0.54

HAS-BLED score

0.92

 0 n (%)

0 (0)

0 (0)

 1 n (%)

2 (0.8)

0 (0)

 2 n (%)

3 (1.2)

1 (4.2)

 3 n (%)

41 (16.5)

4 (16.7)

 4 n (%)

76 (31.0)

8 (33.3)

 5 n (%)

76 (31.0)

7 (29.4)

 6 n (%)

36 (15.4)

4 (16.7)

 7 n (%)

9 (3.7)

0 (0)

 8 n (%)

1 (0.4)

0 (0)

 9 n (%)

0 (0)

0 (0)